


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 15/87, A61K 48/00	A1	(11) International Publication Number: WO 00/15825 (43) International Publication Date: 23 March 2000 (23.03.00)
(21) International Application Number: PCT/US98/19067 (22) International Filing Date: 11 September 1998 (11.09.98) (71) Applicant: SEQUUS PHARMACEUTICALS, INC. [US/US]; 960 Hamilton Court, Menlo Park, CA 94025 (US) (72) Inventors: HUANG, Shi, Kun; 18798 Madison Avenue, Castro Valley, CA 94546 (US). OTO, Edwin, Kiyoshi; 1121 St. Francis Street, Redwood City, CA 94061 (US). HASSANIPOUR, Mohammad; 1023 Topsail Drive, Vallejo, CA 94591 (US). JIN, Bei; 4546 Cape View Drive, Union City, CA 94587 (US). (74) Agents: MOHR, Judy, M. et al.; Dehlinger & Associates, P.O. Box 60850, Palo Alto, CA 94306-0850 (US).	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AR&PO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	

Published*With international search report.***(54) Title: CONDENSED PLASMID-LIPOSOME COMPLEX FOR TRANSFECTION****(57) Abstract**

A plasmid-liposome composition for transfection of a cell is described. The composition includes plasmid molecules condensed with a polycationic condensing agent and cationic liposomes. Also disclosed is a method for preparing the plasmid-liposome complexes.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republik of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

CONDENSED PLASMID-LIPOSOME COMPLEX FOR TRANSFECTION

Field of the Invention

The present invention relates to an improvement in a method for preparing plasmid-
5 liposome complexes for *in vivo* transfection of a gene and to compositions prepared by the
method.

References

10 Felgner, J., *et al.*, *Proc. Natl. Acad. Sci. USA* 84:7413-7417 (1987).

15 Felgner, J., *et al.*, *J. Tiss. Cult. Meth.* 15:63-68 (1993).

Gao, X., and Huang, L., *Biochemistry* 35:1027-1036 (1996).

Guo, L., *et al.*, *Journal of Liposome Research* 3(1):51-70 (1993).

Li, S., and Huang, L., *Journal of Liposome Research*, 6(3):589-608 (1996).

Mulligan, R.S., *Science* 260:926-932 (1993).

15 Morishita, R., *et al.*, *J. Clin. Invest.* 91:2580-2585 (1993).

Rose, J.K., U.S. Patent No. 5,279,833 (1994).

Trubetskoy, V.S., *et al.*, *Biochimica et Biophysica Acta* 1131:311-313 (1992).

20 Wagner, E., *et al.*, *Proc. Natl. Acad. Sci. USA* 88:4255-4259 (1991).

Background of the Invention

A variety of methods have been developed to facilitate the transfer of genetic material into specific cells, *e.g.*, gene therapy. These methods are useful for both *in vivo* or *ex vivo* gene transfer. In the former, a gene is directly introduced (intravenously, intraperitoneally, aerosol, etc.) into a subject. In *ex vivo* (or *in vitro*) gene transfer, the gene 25 is introduced into cells after removal of the cells from specific tissue of an individual. The transfected cells are then introduced back into the subject.

Delivery systems for achieving *in vivo* and *ex vivo* gene therapy include viral vectors, such as a retroviral vector or adenovirus vectors, microinjection, electroporation, protoplast fusion, calcium phosphate, and liposomes (Felgner, *et al.*, 1987; Mulligan, 1993; 30 Morishita, *et al.*, 1993).

Liposomal mediated gene therapy has, for example, involved the use of cationic liposomes formed from LIPOFECTIN, a reagent consisting of a cationic lipid and a neutral lipid (Felgner, *et al.*, 1989, 1993). Other liposomal-mediated methods of gene therapy have been described (Trubetskoy, *et al.*, 1992; Morishita, *et al.*, 1993; Rose, 1994), where

apparent when the following detailed description of the invention is read in conjunction with the accompanying drawings.

Brief Description of the Drawings

5 Fig. 1 is a computer-generated image of an electron micrograph of a plasmid condensed with the polycationic polymer total histone;

Fig. 2 is a computer-generated image of an electron micrograph of a polycation-condensed plasmid complexed with cationic liposomes in accordance with the invention;

10 Figs. 3A-3B are computer-generated images of cryogenic (Fig. 3A) and freeze fracture (Fig. 3B) transmission electron micrographs of a polycation-condensed plasmid complexed with cationic liposomes in accordance with the invention;

Fig. 4 is a plot showing the size, in nm as measured by dynamic light scattering, of plasmid-liposome complexes prepared in accordance with the invention;

15 Fig. 5 is a plot of particle diameter, in nm as measured by dynamic light scattering, as a function of storage time at 4 C, for plasmid-liposome complexes of the invention;

Fig. 6 is a plot of percent of injected dose as a function of time after intravenous injection in mice of labeled plasmid-liposome complexes of the invention;

20 Figs. 7A-7E show luciferase expression, in relative light units (RLU)/10 seconds/mg protein, in the lung (Fig. 7A), liver (Fig. 7B), heart (Fig. 7C), spleen (Fig. 7D) and kidney (Fig. 7E) for plasmid-liposome complexes prepared with total histone;

Figs. 8A-8E show luciferase expression, in relative light units (RLU)/10 seconds/mg protein, in the lung (Fig. 8A), liver (Fig. 8B), heart (Fig. 8C), spleen (Fig. 8D) and kidney (Fig. 8E) for plasmid-liposome complexes prepared with histone H1;

25 Figs. 9A-9E show luciferase expression, in relative light units (RLU)/10 seconds/mg protein, in the lung (Fig. 9A), liver (Fig. 9B), heart (Fig. 9C), spleen (Fig. 9D) and kidney (Fig. 9E) for plasmid-liposome complexes prepared with histone H4;

Figs. 10A-10E show luciferase expression, in pg luciferase/mg protein, in the lung (Fig. 10A), liver (Fig. 10B), heart (Fig. 10C), spleen (Fig. 10D) and kidney (Fig. 10E) for plasmid-liposome complexes prepared with poly-L-glutamine, melittin or polymyxin B as 30 the cationic condensing agent;

Figs. 11A-11B show luciferase expression in the lung (Fig. 11A) and the liver (Fig. 11B) as a function of time in days for plasmid-liposome complexes stored at 4 °C;

Fig. 12 shows luciferase in various tissues, in pg/mg protein, at 24 hours after intravenous administration in mice of plasmid-liposome complexes, as a function of

micrograms of luciferase-carrying plasmid;

Fig. 13 shows luciferase activity, in RLU/mg protein, in various tissues 24 hours after intravenous administration of plasmid-liposome complexes;

5 Figs. 14A-14B show percent of surviving animals as a function of days post inoculation with Lewis lung metastasis, for animals treated with plasmid-liposome complexes including the plasmids pHHSVtk (Fig. 14A), pCMVp53 (Fig. 14B) and pCMVIL2 (Fig. 14C);

10 Fig. 15 is a plot showing the body weight, in grams, of mice following administration of plasmid-liposome complexes prepared with a pNSL plasmid encoding for luciferase as a function of time in days. The mice were treated on days 1, 8, 15, 22 and 28, as indicated by the arrows in the plot, with saline (plus symbols), and plasmid-liposome complexes at dosages of 50 μ g plasmid (open circles), 75 μ g plasmid (closed triangles) and 100 μ g plasmid (open, inverted triangles); and

15 Fig. 16 is a plot showing luciferase expression, in ng/mg protein, in various mice tissues 24 hours after administration of plasmid-liposome complexes prepared with pNSL plasmid encoding for luciferase to tumor-bearing mice (metastasis model of Lewis Lung Tumor).

Detailed Description of the Invention

20 I. Plasmid-Liposome Complex

The present invention is directed to a plasmid-liposome complex, and to an improvement in a method of preparing such a complex, for use in *in vivo* transfection of a host cell. The composition includes plasmid molecules which are condensed with a polycationic condensing agent and then suspended in low-ionic strength medium. The 25 condensed plasmid molecules are mixed with lipid particles, such as liposomes, to form plasmid-liposome complexes. The improvement in the method of preparation, as will be described, relates to selection of the condensing agent, selection of the suspension medium and selection of the liposome lipid to plasmid ratio. Before describing the improved preparation procedure in detail, the plasmid-liposome complex and its components will be 30 described.

A. Cationic Liposome Components and Preparation

As described above, the plasmid-liposome complex includes condensed plasmid molecules and liposomes. Liposomes, as used herein, refer to lipid vesicles having an

outer lipid shell, typically formed on one or more lipid bilayers, encapsulating an aqueous interior. In a preferred embodiment, the liposomes are cationic liposomes composed of between about 20-80 mole percent of a cationic vesicle-forming lipid, with the remainder neutral vesicle-forming lipids and/or other components. As used herein, "vesicle-forming lipid" refers to any amphipathic lipid having hydrophobic and polar head group moieties and which by itself can form spontaneously into bilayer vesicles in water, as exemplified by phospholipids. A preferred vesicle-forming lipid is a diacyl-chain lipid, such as a phospholipid, whose acyl chains are typically between about 14-22 carbon atoms in length, and have varying degrees of unsaturation.

10 A cationic vesicle-forming lipid is one whose polar head group with a net positive charge, at the operational pH, *e.g.*, pH 4-9. Typical examples include phospholipids, such as phosphatidylethanolamine, whose polar head groups are derivatized with a positive moiety, *e.g.*, lysine, as illustrated, for example, for the lipid DOPE derivatized with L-lysine (LYS-DOPE) (Guo, *et al.*, 1993). Also included in this class are the glycolipids, such as 15 cerebrosides and gangliosides having a cationic polar head-group.

Another cationic vesicle-forming lipid which may be employed is cholesterol amine and related cationic sterols. Exemplary cationic lipids include 1,2-dioleyloxy-3-(trimethylamino) propane (DOTAP); N-[1-(2,3,-ditetradecyloxy)propyl]-N,N-dimethyl-N-hydroxyethylammonium bromide (DMRIE); N-[1-(2,3,-dioleyloxy)propyl]-N,N-dimethyl-20 N-hydroxy ethylammonium bromide (DORIE); N-[1-(2,3-dioleyloxy) propyl]-N,N,N-trimethylammonium chloride (DOTMA); 3 β [N-(N',N'-dimethylaminoethane) carbamoly] cholesterol (DC-Chol); and dimethyldioctadecylammonium (DDAB).

25 The remainder of the liposomes are formed of neutral vesicle-forming lipids, meaning vesicle forming lipids which have no net charge or which may include a small percentage of lipids having a negative charge in the polar head group. Included in this class of lipids are the phospholipids, such as phosphatidylcholine (PC), phosphatidyl ethanolamine (PE), phosphatidylinositol (PI), and sphingomyelin (SM), and cholesterol, cholesterol derivatives, and other uncharged sterols.

30 The above-described lipids can be obtained commercially, or prepared according to published methods. Other lipids that can be included in the invention are glycolipids, such as cerebrosides and gangliosides.

In one embodiment of the invention, the plasmid-liposome complex includes liposomes having a surface coating of hydrophilic polymer chains, effective to extend the blood circulation time of the plasmid/liposome complexes. Suitable hydrophilic polymers

include polyethylene glycol (PEG), polylactic acid, polyglycolic acid, polyvinyl-pyrrolidone, polymethyloxazoline, polyethyloxazoline, polyhydroxypropyl methacrylamide, polymethacrylamide, polydimethylacrylamide, and derivatized celluloses, such as hydroxymethylcellulose or hydroxyethyl-cellulose. A preferred hydrophilic polymer chain 5 is polyethyleneglycol (PEG), preferably as a PEG chain having a molecular weight between 500-10,000 daltons, more preferably between 1,000-5,000 daltons. The hydrophilic polymer may have solubility in water and in a non-aqueous solvent, such as chloroform.

The coating is preferably prepared by including in the vesicle-forming lipids 10 forming the liposomes, between 1-20 mole percent of a vesicle-forming lipid, preferably a phospholipid or other diacyl-chain lipid, derivatized at its head group with the polymer chain. Exemplary methods of preparing such lipids, and forming polymer coated liposomes therewith, have been described in U.S. Patents Nos. 5,013,556, and 5,395,619.

It will be appreciated that the hydrophilic polymer can be stably coupled to the 15 lipid, or coupled through an unstable linkage which allows the polymer-coated plasmid-liposome complexes to shed or "release" the hydrophilic polymer coating during circulation in the bloodstream or after localization at a target site. Attachment of hydrophilic polymers, in particular polyethyleneglycol (PEG), to vesicle-forming lipids through a bond effective to release the polymer chains in response to a stimulus have been 20 described, for example in WO 98/16202 and WO 98/16201, and by Kirpotin, D. *et al.* (*FEBS Letters*, 388:115-118 (1996)).

The releasable linkage, in one embodiment, is a chemically releasable linkage which is cleaved by administration of a suitable releasing agent or is cleaved under 25 selective physiological conditions, such as in the presence of enzymes or reducing agents. For example, ester and peptide linkages are cleaved by esterase or peptidase enzymes. Disulfide linkages are cleaved by administration of a reducing agent, such as glutathione or ascorbate, or by a reducing agent present *in vivo*, such as cysteine, which is present in plasma and intracellularly.

Other releasable linkages include pH sensitive bonds and bonds which are cleaved 30 upon exposure to glucose, light or heat. By way of an example, the hydrophilic polymer chains can be attached to the liposome by a pH sensitive bond, and the plasmid-liposome complexes are targeted to a site having a pH effective to cleave the bond and release the hydrophilic chains, such as a tumor region. Exemplary pH sensitive bonds include acyloxyalkyl ether, acetal and ketal bonds. Another example is where the cleavable bond

is a disulfide bond, broadly intended herein to refer to sulfur-containing bonds. Sulfur-containing bonds can be synthesized to achieve a selected degree of lability and include disulfide bonds, mixed sulfide-sulfone bonds and sulfide-sulfoxide bonds. Of the three bonds, the disulfide bond is least susceptible to thiolysis and the sulfide-sulfoxide bond is 5 most susceptible.

Such releasable bonds are useful to tailor the rate of release of the hydrophilic polymer segment from the plasmid-liposome complexes. For example, a very labile disulfide bond can be used for targeting to blood cells or endothelial cells, since these cells are readily accessible and a shorter liposome blood circulation lifetime is sufficient. At the 10 other extreme, a long-lasting or hearty disulfide bond can be used when the target is tumor tissue or other organs where a longer liposome blood circulation lifetime is generally needed for the complexes to reach the desired target.

The releasable bond attaching the hydrophilic polymer chains to the liposome is cleaved *in vivo* typically as a result of change in environment, such as when the liposomes 15 reach a specific site with a slightly lower pH, such as a region of tumor tissue, or a site with reducing conditions, such as a hypoxic tumor. Reducing conditions *in vivo* can also be effected by administration of a reducing agent, such as ascorbate, cysteine or glutathione. The cleavable bond may also be broken in response to an external stimuli, such as light or heat.

20 In another embodiment, the plasmid-liposome complexes include an affinity moiety or targeting ligand effective to bind specifically to target cells at which the therapy is aimed. Such moieties can be attached to the surface of the liposome or to the distal ends of hydrophilic polymer chains. Exemplary moieties include antibodies, ligands for specific binding to target cell surface receptors and the like, as described, for example, in PCT 25 application Nos. WO US94/03103, WO 98/16202 and WO 98/16201. The moiety can also be a hydrophobic segment to facilitate fusion of the complex with a target cell.

B. Condensed Plasmid

30 This section describes the preparation of the condensed-phase plasmid employed in the plasmid-liposome complex of the invention.

Polycationic condensing agents used to condense the plasmid are multiply charged cationic polymers, typically biopolymers such as such as spermidine, spermine, polylysine, protamine, total histone, specific histone fractions such as H1, H2, H3, H4, and other polycationic polypeptides, but may also include biocompatible polymers, such as

polymyxin B. It will be appreciated that these polycationic condensing agents can be used in free base or salt forms, for example, protamine sulfate and polylysine hydrobromide. In a preferred embodiment, the polycationic condensing agent is a histone, which, as referred to herein, includes total histone or specific histone fractions.

5 Plasmids suitable for use in the complex are preferably circularized or closed double-stranded molecules having sizes preferably in the 5-40 Kbp (kilo basepair) range. The plasmids are constructed according to well-known methods and include a therapeutic gene, *i.e.*, the gene to be expressed in gene therapy, under the control of suitable promoter and terminator control elements, and other elements necessary for replication within the 10 host cell and/or integration into the host-cell genome. Methods for preparing plasmids useful for gene therapy in genes or other mammals are widely known and referenced.

The genes to be introduced for gene therapy by the complex of the invention generally fall into one of three categories:

In the first are those genes which are intended to overcome a gene deficiency or 15 defect in the subject, *i.e.*, where the subject fails to produce active, endogenous protein at all or within normal levels, and the gene introduced in the plasmid is intended to make up this deficiency. Examples of this class of genes include genes encoding adenosine deaminase (ADA), for gene expression in stem cells or lymphocytes; genes encoding purine nucleoside phosphorylase deficiency, deficiency in prostaglandin G/H synthase, 20 therapy of Lesch-Nyhan syndrome caused by a deficiency in hypoxanthine-guanine phosphoribosyltransferase, genes encoding a variety of circulating proteins, such as α_1 -antitrypsin, clotting factors (*e.g.*, Factor VIII, Factor IX) and globins (*e.g.*, β -globin, hemoglobin), for the treatment of hemophilia, sickle-cell anemia and other blood-related diseases, and genes encoding hormones and other peptide regulators.

25 In the second class are polypeptides designed to treat any existing pathology, such as cancer, or a pathogenic condition such as viral infection. Examples include gene therapy to supply the p53 gene for cancer therapy, the gene for the CD4 peptide to inhibit HIV infection, the gene for the *Pseudomonas* peptide to inhibit binding of *Pseudomonas* to epithelial cells, and specific antibody genes to inhibit a targeted pathogen.

30 The third class includes genes intended to produce an mRNA transcript that can act as an antisense molecule to inhibit an undesirable protein expression, such as overexpression of proteins specific for tumor growth, or expression of viral proteins.

II. Preparation and Characterization of the Complex

In accordance with the invention, it has been discovered that a plasmid-liposome complex formed by mixing condensed-phase plasmid and cationic liposomes, in a low ionic strength medium, produces complexes having a substantially homogeneous size of 5 typically less than about 200 nm and preferably in the range of 50-200 nm, more preferably between 100-200 and most preferably between 120-180 nm. The complexes are further characterized by a retention of activity of the expression of the encoded gene, that is, the complexes have a transfection stability. This is evidenced by the ability of the complexes after storage for 30 days, and preferably 90 days, at 4 °C, to transfect cells and achieve 10 expression of the encoded gene, as will be discussed below.

The condensed-phase plasmid is formed by adding to the plasmid, in a low-ionic strength medium, a polycationic polymer condensing agent of the type identified above. The cationic polymer is added to the plasmid solution to a preferred concentration at which 15 charge stoichiometry is achieved, *i.e.*, where the total number of charges in the cationic polymer (as determined from the polymer's known charge density/weight) is at least as great as the total negative charge of the DNA (as determined from the weight amount plasmid and the known charge density of DNA/weight). Typically, the weight ratio of added DNA plasmid to added polymer is between about 0.1-5.0, more preferably, between 0.3-2.0. The condensing agent is preferably added slowly to the plasmid suspension with 20 stirring, *e.g.*, over a 10 minute period.

The condensed plasmid and cationic liposomes, both contained in a low-ionic strength medium, are then mixed, *e.g.*, by slow addition of the condensed plasmid molecules to the liposomes. The ratio of liposome lipids to plasmid is an important parameter for achieving maximum transfection. That ratio, in nmole liposome lipid/μg 25 plasmid, is greater than 5 but less than 25, preferably greater than 8 but less than 18, more preferably greater than 10 but less than 15 and most preferably between 12-14.

As indicated above, a critical feature of the invention is the mixing of liposomes and condensed phase plasmid in a low ionic-strength medium. Preferably the final concentration of the medium, including ions present in the DNA, condensing agent, and 30 liposome lipid species, is less than the ionic strength of a 25 mM monovalent ionizable salt, such as NaCl, and preferably less than 10 mM of such salt, more preferably less than about 1 mM. In general, low ionic strength is readily obtained by employing free base or free acid plasmid, polycation, and lipid species, removing electrolyte components, or alternatively, employing sufficiently dilute concentrations of the components to maintain a

low ionic strength, and/or removing electrolytes generated from the components by dialysis or the like. At the same time, it is useful to prepare the composition in the presence of a non-electrolyte solute such as glucose to provide an osmotic balance as an injectable formulation.

5 Fig. 1 is a computer-generated image of a negative-stain transmission electron micrograph of a luciferase-encoding pNSL plasmid condensed with total histone, prepared as described in Example 1. As seen, the plasmid is condensed into discrete, single particles of about 100 nm in diameter and less.

Fig. 2 is a computer-generated image of a negative-stain transmission electron micrograph of a polycation-condensed plasmid-liposome complex prepared as described in Example 1. In comparing the neat, condensed plasmid molecules in Fig. 1 with the complex of Fig. 2, the opaque, condensed plasmids are readily apparent in Fig. 2. Also visible in Fig. 2 is a transparent membrane which surrounds each condensed plasmid. This transparent membrane is the liposome lipid bilayer which coats each condensed plasmid.

15 Figs. 3A-3B are computer-generated images of cryo-electron and freeze fracture transmission electron micrographs of the plasmid-liposome complex prepared as described in Example 1. The micrograph in Fig. 3A is obtained by freezing a thin layer of plasmid-liposome complex suspension and viewing the layer under a cryoelectro microscope. The micrograph shows single, discrete plasmid-liposome complexes, where the condensed 20 DNA is visible as a darker central region in many of the particles. The freeze-fracture micrograph of Fig. 3B also shows discrete plasmid-liposome complexes, with no apparent aggregation.

Dynamic light scattering was used to determine the average complex size and size distribution. The results are shown in Fig. 4 which shows that the complexes as prepared 25 in Example 1 form a homogeneous population having an average size of about 146 nm (standard deviation of 45 nm). This and other studies performed in support of the invention indicate that the composition when prepared according to the described method achieves complexes having a homogeneous population, as evidenced by a single peak indicating a population of complexes having a relatively narrow size distribution.

30 Preferably, complexes have a size of less than 200 nm, more preferably between 50-200 nm, most preferably between 100-200 and still more preferably between 120-180 nm.

As briefly discussed above, the plasmid-liposome complexes are stable, that is, the complexes maintain their initial size, *e.g.*, there is little aggregation of the complexes, and the complexes retain therapeutic activity, for at least 30 days after storage at 4 °C. Fig. 5

provides evidence of complex size stability and shows the complex size, as measured by dynamic light scattering, as a function of time. A suspension of the plasmid-liposome complexes in water/glucose were stored at 4 °C and analyzed after 7, 14, 21, 28, 60 and 90 days of storage. Initially after complex formation, the average complex size was about 150 nm and, as seen, after 90 days of storage, the complex size remained at about 150 nm. Complex stability with respect to retention of therapeutic activity is discussed below in Figs. 11A-11B.

III. In vivo Transfection

Plasmid-liposome complexes prepared in accordance with the invention were administered to mice to determine the transfection efficiency of various plasmid-liposome complex formulations and to determine stability of transfection, biodistribution of the complex, pharmacokinetics and dose response. The exemplary *in vivo* transfection procedure is described in Example 2.

S 35

The pharmacokinetics of plasmid-liposome complexes were determined by injecting complexes including an S³⁵-labelled DNA plasmid into mice. Fig. 6 shows the percent of injected dose as a function of time after intravenous injection. Immediately after injection of the plasmid-liposome complex, about 7% of the injected dose is in the blood stream. Other studies have determined that the remaining percentage of the complexes localize in the lung immediately after injection. After a period of time the complexes are neutralized by serum proteins in the lung and enter the blood stream, as evidenced by the increase in the percentage of injected dose to about 22% at the 5 hour time point (Fig. 6). The complexes are then cleared from the bloodstream, with about 12% of the injected dose present at 24 hours.

Plasmid-liposome complexes were prepared for *in vivo* administration with varying ratios of liposome lipid to plasmid. The complexes were prepared according to the general procedure set forth in Example 1 by varying the amount of polycation condensing agent, and the total amount of liposome lipids. Typically, the amount of polycation condensing agent varied between 100-500 µg and the liposome lipid/plasmid ratio varied between 8-18 nmoles lipid/µg plasmid.

Figs. 7-9 show the results for plasmid-liposome complexes prepared with total histone (Figs. 7A-7E), histone H1 (Figs. 8A-8E) and histone H4 (Figs. 9A-9E) as the polycationic condensing agents. After administration of the complex, prepared from the formulations indicated in the tables below, luciferase expression was measured in the lung,

liver, heart, spleen and kidney.

Table 1 summarizes the compositions for the plasmid-liposome complexes prepared using total histone as the polycationic condensing agent. The amount of total histone was varied between 100-500 μ g to vary the ratio of plasmid/total histone from 0.2-
5 1.0. The ratio of liposome lipids/plasmid was also varied and ratios of 8, 14 and 18 nmoles liposome lipids/ μ g plasmid were tested.

Table 1

Component	Formulation Number ¹					
	1	2	3	4	5	6
pNSL plasmid, μ g	100	100	100	100	100	100
total histone, μ g	200	100	200	350	500	200
μ moles liposome lipids ²	0.8	1.4	1.4	1.4	1.4	1.8
μ g plasmid/ μ g total histone	0.5	1.0	0.5	0.3	0.2	0.5
nmoles lipids/ μ g plasmid	8	14	14	14	14	18

¹*In vivo* results for each formulation number shown in Figs. 7A-7E.

²Liposome prepared from 1:1 mole ratio of DDAB:cholesterol.

10

The results of *in vivo* administration in mice of the formulations summarized in Table 1 are shown in Figs. 7A-7E, where luciferase expression, in relative light units (RLU)/10 seconds/mg protein, is shown in the lung (Fig. 7A), liver (Fig. 7B), heart (Fig. 15 7C), spleen (Fig. 7D) and kidney (Fig. 7E). The figures indicate that there is a window where the transfection is highest. Specifically, for total histone as the condensing agent, the transfection is highest where the liposome lipid/plasmid ratio is greater than 8 nmoles lipid/ μ g plasmid and less than 18 nmoles lipid/ μ g.

Table 2 summarizes the plasmid-liposome complex compositions prepared and
20 tested *in vivo* using histone H1 as the polycationic condensing agent. The ratio of plasmid/histone H1 ratio was 0.3 or 0.5 and the liposome lipid/plasmid ratio was varied from 8, 14 and 18 nmoles lipid/ μ g plasmid.

Table 2

Component	Formulation Number ¹				
	7	8	9	10	11
pNSL plasmid, μ g	100	100	100	100	100
histone H1, μ g	350	200	350	200	350
μ moles liposome lipids ²	0.8	1.4	1.4	1.4	1.4
μ g plasmid/ μ g histone H1	0.3	0.5	0.3	0.5	0.3
nmoles lipids/ μ g plasmid	8	14	14	18	18

¹In vivo results for each formulation number shown in Figs. 8A-8E.

²Liposomes prepared from 1:1 mole ratio of DDAB:cholesterol.

5 The results of *in vivo* administration in mice of the formulations summarized in Table 2 are shown in Figs. 8A-8E, where luciferase expression, in relative light units (RLU)/10 seconds/mg protein, is shown in the lung (Fig. 8A), liver (Fig. 8B), heart (Fig. 8C), spleen (Fig. 8D) and kidney (Fig. 8E). The figures indicate that the best transfection is achieved at a liposome lipid/plasmid ratios of 14 and 18.

10 Tables 3A and 3B summarize the formulations of plasmid-liposome complexes formed using histone H4 as the polycationic condensing agent. The plasmid/histone H4 ratio varied from 0.2, 0.3 or 0.5 and the liposome lipid/plasmid ratio was varied from 8, 14 or 18 nmoles lipid/ μ g plasmid.

15

Table 3A

Component	Formulation Number ¹			
	12	13	14	15
pNSL plasmid, μ g	100	100	100	100
histone H4, μ g	200	350	500	200
μ moles liposome lipids ²	0.8	0.8	0.8	1.4
μ g plasmid/ μ g histone H4	0.2	0.3	0.2	0.5
nmoles lipids/ μ g plasmid	8	8	8	14

¹In vivo results for each formulation number shown in Figs. 9A-9E.

²Liposomes prepared from 1:1 mole ratio of DDAB:cholesterol.

Table 3B

Component	Formulation Number ¹				
	16	17	18	19	20
pNSL plasmid, μ g	100	100	100	100	100
histone H4, μ g	350	500	200	350	500
μ moles liposome lipids ²	1.4	1.4	1.8	1.8	1.8
μ g plasmid/ μ g histone H4	0.3	0.2	0.5	0.3	0.2
nmoles lipids/ μ g plasmid	14	14	18	18	18

¹*In vivo* results for each formulation number shown in Figs. 9A-9E.

²Liposomes prepared from 1:1 mole ratio of DDAB:cholesterol.

5 The results of *in vivo* administration in mice of the formulations summarized in
 Tables 3A and 3B are shown in Figs. 9A-9E, where luciferase expression, in relative light
 units (RLU)/10 seconds/mg protein, is shown in the lung (Fig. 9A), liver (Fig. 9B), heart
 (Fig. 9C), spleen (Fig. 9D) and kidney (Fig. 9E). There is a window where transfection is
 highest of greater than 8 nmoles liposome lipid/ μ g plasmid and less than 18 nmoles
 10 liposome lipid/ μ g plasmid.

In other experiments performed in support of the present invention, plasmid-
 liposome complexes were prepared using poly-L-glutamine, melittin (a low molecular
 weight peptide containing 26 amino acids) or polymyxin B sulfate as polycationic
 condensing agents. Each of these are commercially available from Sigma Chemical Co.
 15 The complexes were injected in mice, as described Example 2, and *in vivo* transfection was
 measured by determining luciferase expression.

Table 4 summarizes the plasmid-liposome complex compositions prepared using
 poly-L-glutamine, melittin or polymyxin B as polycationic condensing agents. The amount
 of condensing agent was varied from 50-200 μ g.

Table 4

condensing agent	Condensing Agent ¹								
	poly-L-glutamine			melittin		polymyxin B			
Formulation No.	21	22	23	24	25	26	27	28	29
pNSL plasmid, μ g	100	100	100	100	100	100	100	100	100
μ g condensing agent	50	100	200	50	100	200	50	100	200
μ moles liposome lipids ²	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
μ g plasmid/ μ g condensing agent	2	1	0.5	2	1	0.5	2	1	0.5
nmoles lipids/ μ g plasmid	14	14	14	14	14	14	14	14	14

¹*In vivo* results for each formulation number shown in Figs. 10A-10E.

²Liposomes prepared from 1:1 mole ratio of DDAB:cholesterol.

5 The results of *in vivo* administration in mice of the plasmid-liposome complexes in Table 4 are shown in Figs. 10A-10E, where luciferase expression, in pg luciferase/mg protein, is shown in the lung (Fig. 10A), liver (Fig. 10B), heart (Fig. 10C), spleen (Fig. 10D) and kidney (Fig. 10E). The lipid/plasmid ratio for each of the formulations was constant at 14 nmoles lipid/ μ g plasmid, falling about midway in the preferred range of 5-25
10 nmoles liposome lipid/ μ g plasmid.

These studies using a variety of polycationic condensing agents, e.g., total histone, histone H1, histone H4, poly-L-glutamine, melittin and polymyxin B, indicate that transfection is achieved when the liposome lipid/plasmid ratio (in nmoles lipid/ μ g plasmid) is greater than 5 and less than about 25. More preferably, the ratio is between 8-18, even
15 more preferably between 10-15 and most preferably between 12-14 nmoles liposome lipid/ μ g plasmid.

As discussed above, the plasmid-liposome complex of the present invention is stable, as evidenced by little change in particle size (see Fig. 5), for as long as 90 days at 4 °C. The expression stability of the complex was determined by administering plasmid-
20 liposome complexes which were stored at 4 °C to mice. Specifically, the suspension of plasmid-liposome complexes was administered intravenously to mice immediately after preparation of the complex (day 0) and at 7, 14, 21, 28, 30 and 90 days after storage at 4 °C. Following the procedure detailed in Example 2, luciferase expression in the lung and liver was determined, and the results are shown in Figs. 11A-11B.

25 As seen in Figs. 11A-11B, luciferase expression in the lung (Fig. 11A) and the liver (Fig. 11B) remain constant as a function of storage time of the complexes. It is clear that

the complex retained the ability to express the encoded gene for the 90 day test period. Accordingly, in one embodiment of the invention that the complex is characterized by the ability to retain more than 50% of the expression activity measured at day 0 for at least 30 days, more preferably for 90 days.

5 A dose-response study was performed using plasmid-liposome complexes prepared as described in Example 1. The plasmid-liposome complex was administered d/r
intravenously in mice at five dosage levels of plasmid: 25, 50, 200 250 and 200 μ g. (Ex 1
P, 19) Twenty-four hours after administration, luciferase expression in the lung, heart, liver, kidney and spleen was measured, and the results are shown in Fig. 12. The luciferase 10 expression measured was proportional to the dose administered, with the highest expression in the lung.

15 The systemic luciferase expression 24 hours following administration of the plasmid-liposome complex in mice is shown in Fig. 13. The plasmid-liposome complex distributes widely, as evidenced by luciferase expression in the bone marrow, lymph nodes and brain. distribution

In another study performed in support of the invention, detailed in Example 3, mice bearing metastatic Lewis lung tumors were treated with plasmid-liposome complexes. After tumor inoculation, the mice were treated with one of eight treatment regimens set forth in Table 5 in Example 3. The treatments included administration of plasmid- 20 liposomes complexes prepared using plasmids carrying genes encoding for p53 (pCMVp53) and interleukin 2 (pCMVIL2) and a combination treatment of ganciclovir and plasmid-liposome complexes prepared with a pHHSVtk (Herpes Simplex Virus thymidine kinase) plasmid. A control group of animals received saline, and comparative groups of animals received complexes prepared with the pNSL plasmid encoding for luciferease 25 (Example 1) or ganciclovir alone. Ex 3

Figs. 14A-14C show the percent of surviving animals as a function of days post tumor-cell inoculation. In all of Figs. 14A-14C, the animals treated with saline are represented with the closed squares. As seen, all of the saline-treated animals died by 24 days after tumor inoculation. In Fig. 14A, the animals treated with complexes including 30 the 50 μ g (solid inverted triangles) and 75 μ g (open squares) pHHSVtk plasmid and with ganciclovir are shown. All of the animals treated with ganciclovir alone (open circles) died by day 37. In contrast, the animals treated with the combination therapy of liposome-plasmid complexes and ganciclovir fared better, with 70% of those treated with the higher plasmid dose surviving the study.

Fig. 14B shows the percent survival of animals treated with plasmid-liposome complexes including pCMVp53 (solid inverted triangles) and pNSL (encoding for luciferase) (open circles). As seen, 20% of the animals treated with complexes including the plasmid encoding for the p53 gene survived the duration of the study, whereas the 5 saline-treated animals (closed squares) and the animals treated with the pNSL plasmid encoding for luciferase-reporter gene died.

Fig. 14C shows the results for animals treated with complexes including the pCMVIL2 plasmid, administered at 50 µg plasmid DNA (inverted solid triangles) and 75 µg plasmid DNA (open squares). As seen, between about 15-20% of the animals survived 10 at the end of the treatment period, whereas left untreated (saline control, solid squares) all of the animals died by day 24. Similarly, animals treated with complexes including the luciferase-encoding pNSL plasmid (open circles) died by day 31.

Formulation number 34 from Table 5 in Example 3, namely the plasmid-liposome complex with the pNSL luciferase-encoding gene, was administered to mice at dosages of 15 50 µg plasmid/0.7 µmol lipid, 75 µg plasmid/1.05 µmol lipid and 100 µg plasmid/1.4 µmol lipid and the body weight of the mice was monitored as an indication of toxicity of the formulation. As seen in Fig. 15, mice treated on days 1, 8, 15, 22 and 28, as indicated by the arrows in the plot, with the complexes had a small loss of weight after the first dose, but recovered any weight loss within a few days. The symbols in the figure are as follows: 20 mice treated with saline (plus symbols) and mice treated with plasmid-liposome complexes at dosages of 50 µg plasmid (open circles), 75 µg plasmid (closed triangles) and 100 µg plasmid (open, inverted triangles).

In another study using the Lewis lung tumor model, the pNSL-luciferase-plasmid-liposome complex was administered to mice and luciferase expression in various tissues 25 was examined 24 hours after administration of plasmid-liposome complexes. As seen in Fig. 16, the highest luciferase expression was observed in the lung and in the tumors.

From the foregoing, it can be appreciated how various features and objects of the invention are met. Plasmid-liposome complexes prepared in accordance with the method of the invention form a substantially homogeneous population having sizes of less than 30 about 200 nm, as evidenced by dynamic light scattering. The complexes are stable for 90 days, with no aggregation of complexes, as evidenced by dynamic light scattering. Importantly, the transfection activity of the complexes is also stable, where the complexes retain more than 50% of transfection efficiency after storage for at least 30 days at 4 °C.

IV. EXAMPLES

The following examples illustrate methods of preparing, characterizing, and using the plasmid-liposome complexes of the present invention. The examples are in no way intended to limit the scope of the invention.

5

Materials and Methods

A. Lipids

Dimethyldioctadecylammonium (DDAB) was purchased from Avanti Polar Lipids, Inc. (Birmingham, AL). Cholesterol, greater than 99% pure, was obtained from Nu-Chek 10 (Elysian, MN).

B. Polycationic Condensing Agents

Total histone, consisting of a mixture of histones, including H1, H2, H3 and H4, histone H1 and histone H4 were obtained from Boehringer Mannheim (Indianapolis, IN). 15 Poly-L-glutamine, melittin and polymyxin B sulfate were obtained from Sigma Chemical Co. (St. Louis, MO).

C. Methods: Dynamic Light Scattering

Size distribution measurements were obtained by dynamic light scattering (DLS) 20 using a Coulter N4MD instrument, operated according to the manufacturer's instructions. The results were expressed as the mean diameter in nm and standard deviation of a Gaussian distribution of particles by relative volume.

Example 1

Preparation of Plasmid-Liposome Complex

A. Preparation of pNSL Plasmid

A pNSL plasmid encoding for luciferase was constructed from two commercially available plasmids, pGFP-N1 plasmid (Clontech, Palo Alto, CA) and pGL3-C (Promega Corporation, Madison, WI).

30 The pGL3-C was cut with *Xba*I and blunt-end ligated using the Klenow fragment of *E. coli* DNA polymerase. It was then cut with *Hind*III and the 1689-bp fragment, carrying the luciferase gene, was gel-purified. The pGFP-N1 plasmid was cut with *Sma*I and *Hind*III and the 4.7 kb fragment, isolated from an agarose gel, was ligated with the luciferase fragment. JM109 *E. coli* cells were transformed and 20 colonies were selected;

about half of them showed the presence of inserts; 8 clones with inserts were cut with *NamHI* and *XhoI* to further confirm the presence of the luciferase gene; 7 of them were positive.

5 B. Preparation of Cationic Liposomes

Cationic liposomes were prepared according to standard procedures by dissolving 10 μ mol DDAB and 10 μ mol cholesterol in an organic solvent containing primarily CHCl₃. The lipids were dried to a thin film by rotation under reduced pressure. The lipid film was hydrated by addition of distilled water to form a suspension of liposomes at a concentration 10 of 20 μ mole/ml. The liposomes were sized by sonication or by sequential extrusion through Nucleopore polycarbonate membranes with pore sizes of 0.4 μ m, 0.2 μ m, 0.1 μ m and 0.05 μ m to obtain liposomes of less than about 200 nm in size (Nucleopore, Pleasanton, CA).

15 C. Preparation of Condensed Plasmid

The DNA plasmid pNSL encoding for luciferase, prepared as described above, was condensed according to the following procedure. 400 μ l of the plasmid (1 mg/ml in distilled water) was diluted with 310 μ l distilled water and then mixed with 90 μ l of 50% glucose. 100 μ l of a polycationic condensing agent (total histone, histone H1, histone H4, 20 poly-L-glutamine, melittin or polymyxin B) from a stock solution of 1 mg/ml in distilled water was added to the plasmid solution slowly with stirring. The mixture was stirred for 10 minutes.

25 D. Preparation of Complex

Plasmid-liposome complexes having a liposome lipid/plasmid ratio of 14 nmole lipid/ μ g plasmid was prepared by diluting 280 μ l of the liposome suspending with 350 μ l of distilled water and then adding 70 μ l of 50% glucose. The suspension of condensed plasmids was slowly added to the diluted cationic liposome suspension with continuous stirring for 10 minutes.

30

Example 2

In vivo Transfection Procedure

In vivo transfection with the plasmid-liposome complexes was conducted with BALB/c mice obtained from Simonsen (Gilroy, CA). Each plasmid-liposome complex

formulation was injected via tail vein into 3 mice. The mice were sacrificed 24 hours after injection and tissues (lung, liver, spleen, kidney, heart) were collected following perfusion with heparinized PBS (4 C) under anesthesia.

At a temperature of between 0-4 °C, 0.75 ml cell lysis reagent (Promega, Madison, 5 WI) was added to each tissue, and the tissue was homogenized for 1 minute at 20,000 rpm. The supernatant was removed to a microcentrifuge tube and spun at 10,000 g for 5 minutes. The supernatant was collected for luciferase and protein assays. 20 µl of each sample was measured immediately by a luminometer (100 µl of luciferin and ATP containing assay buffer, 10 second measurement). The relative light unit was normalized 10 by the amount of protein in the extracts.

Example 3

In vivo Transfection Tumor-Bearing Mice

15 A. Preparation of Plasmid-Liposome Complexes

Plasmid-liposome complexes were prepared according to the procedure of Example 1 using the following plasmids: pNSL encoding for luciferase, prepared as described in Example 1, and pCMVp53, pCMVIL2 and pHHSVtk (all commercially available).

20 B. Tumor Inoculation

Eighty B6C3-F1 male mice were obtained from Taconic Farms (German Town, NY) and allowed to acclimate for 3 days prior to initiation of the experiment. Animals were housed in appropriate isolated caging with *ad lib* sterile rodent food and acidified water and a 12:12 light:dark cycle. Animals were randomized into treatment groups prior 25 to inoculation of tumors based on body weight. Animals were randomized into treatment groups prior to inoculation of tumors.

All the animals were observed daily for general well-being. The animals were weighed prior to inoculation of tumor cells and twice weekly thereafter. Animals observed to have a 15% or greater weight loss from their starting weight, or any animal in distress, 30 was euthanized and examined for the presence and size of metastatic foci in the lung, liver and spleen.

Tumors were inoculated by taking growing Lewis lung tumors from other B6C3-F1 mice by sterile surgical harvest after euthanasia. The tumors were mechanically minced as finely as possible and briefly digested in an enzyme mix of collagenase, protease and

DNAse at 37 °C. After digestion and washing in media (RPMI + 15% FCS) cells were counted with a hemocytometer. Cells were spun down and resuspended in media at 10⁶ cells per ml (10⁵ cells per 0.1 ml injection). The resuspended cells were drawn into individual syringes (0.1 ml, with continuous mixing) for intravenous injection into the tail vein of each animal.

C. Treatment

Animals were treated, beginning 3 days after inoculation with tumor cells, with one of the eight regimens set forth in Table 5. The 10 animals in each group were treated 5 times at one-week intervals, except as indicated for the ganciclovir treatment group no. 30 and for the animals receiving ganciclovir as part of a combination therapy (group nos. 32, 33).

Table 5

Formulation No.	Composition
30 ^{1,2,3,4}	saline, 0.1 ml IV
31 ¹	ganciclovir, 100 µg/kg IP twice daily for 6 days for 5 weeks
32 ¹	liposome/pHSVtk complex, 50 µg DNA/mouse + ganciclovir 100 µg/kg twice daily for 6 days after each administration of the plasmid/liposome complex
33 ¹	liposome/pHSVtk complex, 75 µg DNA/mouse + ganciclovir 100 µg/kg twice daily for 6 days after each administration of the plasmid/liposome complex.
34 ^{2,3,4,5}	liposome/pNSL (luciferase encoding) complex; varying doses of 50, 75, 100 µg plasmid
35 ²	liposome/pCMVp53 complex, 75 µg DNA/mouse
36 ³	liposome/pCMVIL2 complex, 50 µg DNA/mouse
37 ³	liposome/pCMVIL2 complex, 75 µg DNA/mouse

¹data presented in Fig. 14A

²data presented in Fig. 14B

³data presented in Fig. 14C

⁴data presented in Fig. 15

⁵data presented in Fig. 16

15

Twenty-four hours after the last treatment, surviving animals were euthanized for tissue and tumor harvest and examination. The percent of surviving animals for each treatment group are shown in Figs. 14A-14C. Toxicity of formulation no. 34 is shown in

Fig. 15 and luciferase expression of formulation no. 34 is shown in Fig. 16.

Although the invention has been described with respect to particular embodiments, it will be apparent to those skilled in the art that various changes and modifications can be
5 made without departing from the invention.

IT IS CLAIMED:

1. A composition of plasmid-liposome complexes for use in transfecting a host cell with a gene contained in a plasmid, comprising
 - 5 condensed plasmid molecules, said molecules condensed with a polycationic condensing agent and suspended in a low-ionic strength aqueous medium, and cationic liposomes comprising a cationic vesicle-forming lipid, wherein said complexes have a ratio of liposome lipid to plasmid of greater than 5 nmole liposome lipid/ μ g plasmid and less than 25 nmole liposome lipid/ μ g plasmid and have a
 - 10 substantially homogeneous size of less than about 200 nm.
2. The composition of claim 1, wherein the condensed plasmid molecules are DNA plasmid molecules containing a gene selected from the group consisting of genes encoding for cystic fibrosis transmembrane conductance regulator, Factor VIII, interleukin-2 or p53.
 - 15 3. The composition of claim 1, wherein the condensing agent is a polycation selected from the group consisting of histones, poly-L-glutamine, protamine, melittin and polymyxin B.
 - 20 4. The composition of claim 3, wherein the condensing agent is a histone selected from total histone, histone 1 and histone 4.
 - 25 5. The composition of claim 1, wherein the ratio of liposome lipid to plasmid is between 8-18 nmole liposome lipid/ μ g plasmid.
 - 30 6. The composition of claim 1, wherein the low-ionic strength aqueous medium is prepared from a non-ionic osmotic solute.
 - 35 7. The composition of claim 6, wherein said solute is selected from the group consisting of glucose, sucrose and dextran.
 - 40 8. The composition of claim 1, wherein the cationic liposomes are composed of a cationic vesicle-forming lipid selected from dimethyldioctadecylammonium (DDAB), 1,2-dioleyloxy-3-(trimethylamino) propane (DOTAP), N-[1-(2,3,-ditetradecyloxy)propyl]-

N,N-dimethyl-N-hydroxyethylammonium bromide (DMRIE), N-[1-(2,3,-dioleyloxy)propyl]-N,N-dimethyl-N-hydroxy ethylammonium bromide (DORIE), N-[1-(2,3-dioleyloxy) propyl]-N,N,N-trimethylammonium chloride (DOTMA), and 3 β [N-(N',N'-dimethylaminoethane) carbamoly] cholesterol (DC-Chol).

5

9. The composition of claim 1, wherein the cationic liposomes further include a neutral vesicle forming lipid.

10. The composition of claim 1, wherein the cationic liposomes further include 10 cholesterol.

11. The composition of claim 1, wherein the cationic liposomes have a surface coating of hydrophilic polymer chains by including a vesicle-forming lipid derivatized with such a hydrophilic polymer.

15

12. The composition of claim 11, wherein at least a portion of the hydrophilic polymer is joined to the vesicle-forming lipid by a bond effective to release the hydrophilic polymer chains in response to an existing or an induced physiologic condition.

20

13. The composition according to claim 11 or claim 12, wherein the plasmid-liposome complexes further include a ligand attached to distal ends of the hydrophilic polymer chains for ligand-specific binding to a receptor molecule on a target cell surface.

25

14. The composition according to claim 11 or claim 12, wherein the hydrophilic polymer is polyethyleneglycol.

30

15. A plasmid-liposome complex according to any one of the preceding claims for use in transfecting a host cell in the lung of a subject with a DNA plasmid selected from the group of genes encoding for cystic fibrosis transmembrane conductance regulator, interleukin-2 and p53.

16. A plasmid-liposome complex according to any one of the preceding claims for use in transfecting a host cell in a tumor in a subject with a DNA plasmid selected from the group of genes encoding for interleukin-2 and p53.

17. An improvement in a method of preparing plasmid-liposome complexes by condensing plasmid molecules and mixing the condensed plasmids with a suspension of cationic liposomes to form plasmid-liposome complexes for use in transfecting a host cell,
5 said improvement comprising the steps of
selecting as a condensing agent for condensing the plasmid molecules, a polycation selected from the group consisting of histones, poly-L-glutamine, protamine, melittin or polymyxin B,
selecting as a medium for suspending said condensed plasmid molecules, a low-
10 ionic strength aqueous medium, and
selecting a ratio of liposome lipid to plasmid of greater than 5 nmole liposome lipid/ μ g plasmid and less than 25 nmole liposome lipid/ μ g plasmid,
where the plasmid-liposome complexes produced by the improvement are substantially homogeneous in size of less than about 200 nm.
15

18. The method of claim 17, wherein said condensing agent is selected from the group consisting of total histone, histone 1 and histone 4.

19. The method of claim 17, wherein said liposome lipid to plasmid ratio is
20 between 8-18 nmole liposome lipid/ μ g plasmid.

20. The method of claim 17, wherein said low-ionic strength aqueous medium is prepared from a non-ionic osmotic solute.

25 21. The method of claim 20, wherein said solute is selected from the group consisting of glucose, sucrose and dextran.

22. The method of claim 17, wherein the cationic liposomes are prepared from cholesterol and DDAB.

30 23. The method of claim 17, wherein said cationic liposomes have a surface coating of hydrophilic polymer chains by including a vesicle-forming lipid derivatized with the hydrophilic polymer.

24. A plasmid-liposome complex prepared according to claim 17 for use in transfecting a host cell with a DNA plasmid containing a gene selected from the group consisting of genes encoding for Factor VIII, interleukin-2 or p53.

5 25. A plasmid-liposome complex prepared according to claim 17 for use in transfecting a host cell in the lung of a subject with a DNA plasmid selected from the group of genes encoding for cystic fibrosis transmembrane conductance regulator, interleukin-2 and p53.

1/13




Fig. 1




Fig. 2

2/13






Fig. 3A



Fig. 3B

3/13

**Fig. 4****Fig. 5**

4/13














Fig. 6






5/13

**Fig. 7A****Fig. 7B****Fig. 7C****Fig. 7D****Fig. 7E**




6/13

**Fig. 8A****Fig. 8B****Fig. 8C****Fig. 8D****Fig. 8E**



7/13

**Fig. 9A****Fig. 9B****Fig. 9C****Fig. 9D****Fig. 9E**



8/13

**Fig. 10A****Fig. 10B****Fig. 10C**

9/13

**Fig. 10D****Fig. 10E**

10/13

**Fig. 11A****Fig. 11B**




Fig. 12







Fig. 13






Fig. 15




Fig. 16

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 98/19067A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/87 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HONG K ET AL: "STABILIZATION OF CATIONIC LIPOSOME-PLASMID DNA COMPLEXES BY POLYAMINES AND POLY(ETHYLENE GLYCOL)-PHOSPHOLIPID CONJUGATES FOR EFFICIENT IN VIVO GENE DELIVERY. 2. CONDENSING THE DNA WITH POLYAMINES PRIOR TO THE FORMATION OF LIPOSOME-PLASMID COMPLEXES" FEBS LETTERS, vol. 400, 1 January 1997, pages 233-237. XP002067585 see page 233, paragraph 5 see page 234, paragraph 2 see page 236, paragraph 2 - page 237, paragraph 1 --- -/-	1-25

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority, claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

23 June 1999

04/08/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Sitch, W

1

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	GAO ET AL: "POTENTIATION OF CATIONIC LIPOSOME-MEDIATED GENE DELIVERY BY POLYCATIONS" BIOCHEMISTRY, vol. 35, 1996, pages 1027-1036, XP002106921 see page 1027 see abstract ---	
A	SORGI ET AL: "PROTAMINE SULFATE ENHANCES LIPID-MEDIATED GENE TRANSFER" GENE THERAPY, vol. 4, no. 9, September 1997, pages 961-968, XP002106922 see page 962, paragraph 2 - paragraph 5 ---	
A	LI ET AL: "PROTAMINE SULFATE PROVIDES ENHANCED AND REPRODUCIBLE INTRAVENOUS GENE TRANSFER BY CATIONIC LIPOSOME/DNA COMPLEX" JOURNAL OF LIPOSOME RESEARCH, vol. 7, no. 2-3, 1997, pages 207-219, XP002106923 see page 207 - page 208 see abstract ---	
A	BOULIKAS ET AL: "HISTONES, PROTAMINE, AND POLYLYSINE BUT NOT POLY (E:K) ENHANCE TRANSFECTION EFFICIENCY" INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 10, no. 2, 1997, pages 317-322, XP002106924 see page 317 see abstract see page 317, paragraph 4 ---	
A	US 5 187 260 A (KARALI SHARIFA ET AL) 16 February 1993 see column 5, line 63 - column 6, line 32 ---	
E	US 5 851 818 A (OTO EDWIN KIYOSHI ET AL) 22 December 1998 see the whole document -----	1-25

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int'l. Application No.

PCT/US 98/19067

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5187260 A	16-02-1993	US 4893425 A	16-01-1990
US 5851818 A	22-12-1998	NONE	